NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMS · Real-Time Price · USD
20.01
-3.67 (-15.50%)
At close: Nov 20, 2024, 4:00 PM
19.99
-0.02 (-0.10%)
Pre-market: Nov 21, 2024, 7:31 AM EST
-15.50%
Market Cap 1.85B
Revenue (ttm) 33.59M
Net Income (ttm) -198.92M
Shares Out 92.39M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,010,911
Open 21.82
Previous Close 23.68
Day's Range 19.59 - 22.44
52-Week Range 8.90 - 26.35
Beta -0.00
Analysts Strong Buy
Price Target 33.80 (+68.92%)
Earnings Date Nov 6, 2024

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in N... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 29
Stock Exchange NASDAQ
Ticker Symbol NAMS
Full Company Profile

Financial Performance

In 2023, NAMS's revenue was $14.09 million, a decrease of -86.28% compared to the previous year's $102.69 million. Losses were -$176.94 million, 681.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price forecast is $33.8, which is an increase of 68.92% from the latest price.

Price Target
$33.8
(68.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P ...

2 days ago - GlobeNewsWire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

19 days ago - GlobeNewsWire

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

23 days ago - GlobeNewsWire

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

NewAmsterdam Pharma's Obicetrapib, a CETP inhibitor, shows promise in reducing LDL-C, addressing unmet cardiovascular needs, and has favorable Phase 3 trial results. Obicetrapib's potential regulatory...

6 weeks ago - Seeking Alpha

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

2 months ago - GlobeNewsWire

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Needham has initiated coverage on NewAmsterdam Pharma Company N.V NAMS, a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.

3 months ago - Benzinga

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

4 months ago - GlobeNewsWire

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

-- Company expects to report topline data in the first quarter of 2025 -- -- Company expects to report topline data in the first quarter of 2025 --

4 months ago - GlobeNewsWire

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

NewAmsterdam Pharma Company N.V. expects data from the BROOKLYN study, using obicetrapib for the treatment of patients with HeFH, in Q3 of 2024. Data from the BROADWAY study, using obicetrapib for the...

4 months ago - Seeking Alpha

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 --

7 months ago - GlobeNewsWire

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Enrollment to continue to the end of April to accommodate strong patient and site interest Enrollment to continue to the end of April to accommodate strong patient and site interest

8 months ago - GlobeNewsWire

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

RICHMOND, Calif.--(BUSINESS WIRE)-- #aging--BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biolog...

8 months ago - Business Wire

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NAARDEN, the Netherlands and MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...

8 months ago - GlobeNewsWire

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...

8 months ago - GlobeNewsWire

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri...

9 months ago - GlobeNewsWire

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating obicetr...

9 months ago - GlobeNewsWire

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...

10 months ago - GlobeNewsWire

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company...

10 months ago - GlobeNewsWire

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NAARDEN, the Netherlands and MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...

10 months ago - GlobeNewsWire

NewAmsterdam Pharma Announces 2024 Strategic Priorities

-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and BROADWAY trial in ASCVD in 4Q 2024 --

11 months ago - GlobeNewsWire

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 –

1 year ago - GlobeNewsWire

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company dev...

1 year ago - GlobeNewsWire

Tessellate BIO Emerges from Stealth

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening o...

Other symbols: REPL
1 year ago - GlobeNewsWire

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial demonstrated positive biomarker indications and good...

1 year ago - Seeking Alpha

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (“CSF”), respectively, indicating potential improvement of cholesterol metabolism in the brain -- -- Obser...

1 year ago - GlobeNewsWire